Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
57
EXAS Quote, Financials, Valuation and Earnings
Last price:
$101.55
Seasonality move
:
13.8%
Day range:
$101.49 - $101.65
52-week range:
$38.81 - $102.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.18x
P/B ratio:
7.69x
Volume:
400.7K
Avg. volume:
8.4M
1-year change:
74.74%
Market cap:
$19.2B
Revenue:
$2.8B
EPS (TTM):
-$5.32
Analysts' Opinion
-
Consensus RatingEXACT Sciences Corp. has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 18 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $104.56, EXACT Sciences Corp. has an estimated upside of 2.98% from its current price of $101.54.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $85.00 representing 16.29% downside risk from its current price of $101.54.
Fair Value
-
According to the consensus of 21 analysts, EXACT Sciences Corp. has 2.98% upside to fair value with a price target of $104.56 per share.
EXAS vs. S&P 500
-
Over the past 5 trading days, EXACT Sciences Corp. has underperformed the S&P 500 by -1.48% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
EXACT Sciences Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
EXACT Sciences Corp. has grown year-over-year revenues for 40 quarters straight. In the most recent quarter EXACT Sciences Corp. reported revenues of $850.7M.
Earnings Growth
-
EXACT Sciences Corp. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter EXACT Sciences Corp. reported earnings per share of -$0.10.
Enterprise value:
20.8B
EV / Invested capital:
4.12x
Price / LTM sales:
6.18x
EV / EBIT:
--
EV / Revenue:
6.74x
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
71.11x
Price / Operating cash flow:
65.21x
Enterprise value / EBITDA:
212.82x
Gross Profit (TTM):
$2.1B
Return On Assets:
-16.27%
Net Income Margin (TTM):
-32.01%
Return On Equity:
-38%
Return On Invested Capital:
-18.87%
Operating Margin:
1.91%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.4B | $2.7B | $3.1B | $708.7M | $850.7M | |
| Gross Profit | $1.7B | $1.9B | $2.1B | $488.2M | $583.9M | |
| Operating Income | -$340.2M | -$237.8M | -$120.8M | -$29.1M | $16.3M | |
| EBITDA | -$113.2M | -$22M | $97.6M | $25.7M | $72.2M | |
| Diluted EPS | -$1.58 | -$1.17 | -$5.32 | -$0.21 | -$0.10 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.6B | $1B | $1.1B | $1.5B | $1.6B | |
| Total Assets | $6.7B | $6.3B | $6.4B | $6.7B | $5.9B | |
| Current Liabilities | $710.2M | $423.7M | $476.5M | $723.7M | $584.3M | |
| Total Liabilities | $3.2B | $3.2B | $3.3B | $3.5B | $3.4B | |
| Total Equity | $3.5B | $3.1B | $3.1B | $3.2B | $2.5B | |
| Total Debt | $2.4B | $2.4B | $2.5B | $2.8B | $2.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $138.6M | $233M | $386.8M | $138.7M | $219.9M | |
| Cash From Investing | $58.3M | -$467.1M | $62.1M | -$81.7M | -$86.5M | |
| Cash From Financing | $159.8M | $231.4M | -$251.7M | -$226K | -$1.5M | |
| Free Cash Flow | -$23.5M | $53.4M | $292.1M | $67.6M | $190M | |
EXAS
Sector
Market Cap
$19.2B
$28.1M
Price % of 52-Week High
98.91%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
0.2%
-1.49%
1-Year Price Total Return
74.74%
-17.13%
Beta (5-Year)
1.417
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$101.66
200-day SMA
Buy
Level
$58.55
Bollinger Bands (100)
Buy
Level
46.43 - 87.79
Chaikin Money Flow
Buy
Level
38.4M
20-day SMA
Buy
Level
$101.41
Relative Strength Index (RSI14)
Buy
Level
84.95
ADX Line
Buy
Level
70.62
Williams %R
Neutral
Level
-65.4971
50-day SMA
Buy
Level
$83.02
MACD (12, 26)
Buy
Level
5.05
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
321M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.1474)
Sell
CA Score
(Annual)
Level (-0.7825)
Buy
Beneish M-Score
(Annual)
Level (-3.3282)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.7843)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Stock Forecast FAQ
In the current month, EXAS has received 3 Buy ratings 18 Hold ratings, and 0 Sell ratings. The EXAS average analyst price target in the past 3 months is $104.56.
-
Where Will EXACT Sciences Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that EXACT Sciences Corp. share price will rise to $104.56 per share over the next 12 months.
-
What Do Analysts Say About EXACT Sciences Corp.?
Analysts are divided on their view about EXACT Sciences Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that EXACT Sciences Corp. is a Sell and believe this share price will drop from its current level to $85.00.
-
What Is EXACT Sciences Corp.'s Price Target?
The price target for EXACT Sciences Corp. over the next 1-year time period is forecast to be $104.56 according to 21 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 18 analysts rate the stock a Hold.
-
Is EXAS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for EXACT Sciences Corp. is a Hold. 18 of 21 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of EXAS?
You can purchase shares of EXACT Sciences Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase EXACT Sciences Corp. shares.
-
What Is The EXACT Sciences Corp. Share Price Today?
EXACT Sciences Corp. was last trading at $101.55 per share. This represents the most recent stock quote for EXACT Sciences Corp.. Yesterday, EXACT Sciences Corp. closed at $101.54 per share.
-
How To Buy EXACT Sciences Corp. Stock Online?
In order to purchase EXACT Sciences Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get EXAS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
EXAS
Sector
P/E ratio
--
23.89x
PEG ratio
-0.05x
-0.01x
P/B ratio
7.69x
1.81x
Price / LTM sales
6.18x
1.59x
Growth Metrics
EXAS
Sector
Revenue growth
20.05%
4.62%
Earnings growth
49.98%
11.06%
Revenue (5-year growth)
25.78%
6.5%
Earnings forecast
$0.16
-$0.21
Profitability
EXAS
Sector
Profitability FY 2024
$1.9B
$3.6M
Return on invested capital
-18.87%
-31.84%
Return on assets
-16.27%
-27.96%
Return on equity
-38%
-37.63%
Earnings Date
Last Earnings Date
Nov
3
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
2
Balance Sheet
EXAS
Sector
Total cash
$1B
$26.4M
Short term investments
$437.1M
$25.7M
Total assets
$6.2B
$76.9M
Long term debt
$2.5B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
